Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

키워드

참고문헌 (45)

1. Cheemerla S, "Global epidemiology of chronic liver disease", Clin Liver Dis(Hoboken), 17, pp.365~370 (2021)
2. Liberal R, "Cirrhosis and autoimmune liver disease : Current understanding", World J Hepatol, 8, pp.1157~1168 (2016)
3. Ikejima K, "Nonalcoholic fatty liver disease and alcohol-related liver disease : From clinical aspects to pathophysiological insights", Clin Mol Hepatol, 26, pp.728~735 (2020)
4. Rinella ME, "A multisociety Delphi consensus statement on new fatty liver disease nomenclature", J Hepatol, 79, pp.1542~1556 (2023)
5. Song SJ, "Can we use old NAFLD data under the new MASLD definition?", J Hepatol (2023)[DOI]
6. Ratziu V, "Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD", J Hepatol (2023)[DOI]
7. Perazzo H, "Changing from NAFLD through MAFLD to MASLD : Similar prevalence and risk factors in a large Brazilian cohort", J Hepatol (2023)[DOI]
8. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
9. Yoshiji H, "Evidence-based clinical practice guidelines for Liver Cirrhosis 2020", J Gastroenterol, 56, pp.593~619 (2021)
10. Dunkelberger JR, "Complement and its role in innate and adaptive immune responses", Cell Res, 20, pp.34~50 (2010)
11. Ricklin D, "Complement in disease : a defence system turning offensive", Nat Rev Nephrol, 12, pp.383~401 (2016)
12. Fan X, "Diagnostic and prognostic significance of complement in patients with alcohol-associated hepatitis", Hepatology, 73, pp.983~997 (2021)
13. Davey Smith G, "Mendelian randomization : genetic anchors for causal inference in epidemiological studies", Hum Mol Genet, 23, pp.R89~R98 (2014)
14. Ferkingstad E, "Large-scale integration of the plasma proteome with genetics and disease", Nat Genet, 53, pp.1712~1721 (2021)
15. Piñero J, "The DisGeNET knowledge platform for disease genomics : 2019 update", Nucleic Acids Res, 48, pp.D845~D855 (2020)
16. Pletscher-Frankild S, "DISEASES : text mining and data integration of disease-gene associations", Methods, 74, pp.83~89 (2015)
17. Chen YW, "PharmOmics : A species-and tissue-specific drug signature database and gene-network-based drug repositioning tool", iScience, 25, pp.104052~ (2022)
18. Zhou Y, "Metascape provides a biologist-oriented resource for the analysis of systems-level datasets", Nat Commun, 10, pp.1523~ (2019)
19. Hemani G, "The MR-Base platform supports systematic causal inference across the human phenome", Elife, 7, pp.e34408~ (2018)
20. Terziroli Beretta-Piccoli B, "Autoimmune hepatitis : Standard treatment and systematic review of alternative treatments", World J Gastroenterol, 23, pp.6030~6048 (2017)
21. Prietl B, "Vitamin D and immune function", Nutrients, 5, pp.2502~2521 (2013)
22. Abe K, "Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis", PLoS One, 15, pp.e0239481~ (2020)
23. Angulo P, "Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid", Hepatology, 31, pp.318~323 (2000)
24. Ogura M, "Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice", J Pharmacol Exp Ther, 328, pp.564~570 (2009)
25. Saeed A, "Impaired hepatic vitamin A metabolism in NAFLD mice leading to vitamin A accumulation in hepatocytes", Cell Mol Gastroenterol Hepatol, 11, pp.309~325 (2021)
26. Song K, "Yesassociated protein in kupffer cells enhances the production of proinflammatory cytokines and promotes the development of nonalcoholic steatohepatitis", Hepatology, 72, pp.72~87 (2020)
27. Enomoto N, "Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production", Gastroenterology, 123, pp.291~300 (2002)
28. Austin AS, "A pilot study to investigate the use of oxpentifylline(pentoxifylline)and thalidomide in portal hypertension secondary to alcoholic cirrhosis", Aliment Pharmacol Ther, 19, pp.79~88 (2004)
29. Patt YZ, "Thalidomide in the treatment of patients with hepatocellular carcinoma : a phase II trial", Cancer, 103, pp.749~755 (2005)
30. Dong G, "Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15", Cancer Med, 7, pp.820~830 (2018)
31. Shin E, "Expression of HLA and autoimmune pathway genes in liver biopsies of young subjects with autoimmune hepatitis type 1", J Pediatr Gastroenterol Nutr, 75, pp.269~275 (2022)
32. Deng H, "Complement C1QC as a potential prognostic marker and therapeutic target in colon carcinoma based on single-cell RNA sequencing and immunohistochemical analysis", Bosn J Basic Med Sci, 22, pp.912~922 (2022)
33. Yang H, "Prognostic and immune-related value of complement C1Q(C1QA, C1QB, and C1QC)in skin cutaneous melanoma", Front Genet, 13, pp.940306~ (2022)
34. Garam N, "FHR-5 serum levels and CFHR5 genetic variations in patients with immune complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy", Front Immunol, 12, pp.720183~ (2021)
35. Hu X, "The clinical significance of plasma CFHR 1-5 in lupus nephropathy", Immunobiology, 224, pp.339~346 (2019)
36. Kim JH, "Gamma subunit of complement component 8 is a neuroinflammation inhibitor", Brain, 144, pp.528~552 (2021)
37. Kim JH, "Protective effects of complement component 8 gamma against blood-brain barrier breakdown", Front Physiol, 12, pp.671250~ (2021)
38. Heinen S, "Factor H-related protein 1(CFHR-1)inhibits complement C5 convertase activity and terminal complex formation", Blood, 114, pp.2439~2447 (2009)
39. Pritchard MT, "Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice", Gastroenterology, 132, pp.1117~1126 (2007)
40. Fratelli M, "Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population", Leuk Lymphoma, 57, pp.1234~1237 (2016)
41. Wu G, "CFHR1 is a potentially downregulated gene in lung adenocarcinoma", Mol Med Rep, 20, pp.3642~3648 (2019)
42. Cohen JI, "Complement and alcoholic liver disease : role of C1q in the pathogenesis of ethanol-induced liver injury in mice", Gastroenterology, 139, pp.664~674 (2010)
43. Zhang DF, "Complement C7 is a novel risk gene for Alzheimer’s disease in Han Chinese", Natl Sci Rev, 6, pp.257~274 (2019)
44. Seol HS, "Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1", Cancer Lett, 372, pp.24~35 (2016)
45. Davies NM, "Reading Mendelian randomisation studies : a guide, glossary, and checklist for clinicians", BMJ, 362, pp.k601~ (2018)

관련 논문AI추천